Simulations Plus, Inc.

347 articles with Simulations Plus, Inc.

• Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results

  11/16/2020

  Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its 2020 fiscal year (FY20) and fourth quarter (4QFY20) ended August 31, 2020.

• Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call

  11/9/2020

  Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2020, ended August 31, 2020, after the close of the financial markets on Monday, November 16, 2020.

• Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference

  11/5/2020

  Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29 th Annual Virtual Healthcare Conference on Tuesday, November 10, 2020. Mr. O’Connor’s presentation will begin at 3:30 p.m. ET and will be webcast live.

• Lixoft Expands MonolixSuite™ in Version 2020R1

  11/3/2020

  Latest release includes enhanced Simulx module, a powerful simulator for clinical trial pharmacometrics

• Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®

  9/29/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into an accelerated second phase of its collaboration with a large pharmaceutical company to tailor its high-throughput pharmacokinetic (HTPK) simulation functionality within ADMET Predictor®

• Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)

  9/15/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®

• Simulations Plus to Present at the LD 500 Virtual Conference

  8/31/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be presenting at the LD 500 Virtual Conference on Wednesday, September 2, 2020,

• Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  8/10/2020

  Simulations Plus, Inc. announced the closing of its previously announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share, which included the full exercise of the underwriters’ option to purchase 272,727 additional shares of common stock.

• Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock

  8/6/2020

  Simulations Plus, Inc. announced the entry into an underwriting agreement relating to the sale of 1,818,182 shares of its common stock at an offering price of $55.00 per share, less underwriting discounts and commission.

• Simulations Plus Announces Proposed Underwritten Public Offering - Aug 04, 2020

  8/4/2020

  Simulations Plus, Inc., a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

• Simulations Plus Reports Third Quarter FY2020 Financial Results

  7/9/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2020 (3QFY20) and the first nine months of fiscal year 2020 (9moFY20), the period ended May 31, 2020.

• Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call

  7/2/2020

  Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on Thursday, July 9, 2020.

• Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference

  5/21/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 17 th Annual Institutional Investor Conference on Wednesday, May 27, 2020, beginning at 10:00 a.m. ET. Each year, Craig-Hallum hosts a multi-industry investo

• Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference

  5/13/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 15th Annual Needham Virtual Technology & Media Conference on Wednesday, May 20, at 10:00 a.m. ET.

• Simulations Plus Reports Record Second Quarter FY2020 Revenue

  4/9/2020

  Simulations Plus, Inc., the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, reported financial results for its second quarter of fiscal year 2020, the period ended February 29, 2020.

•  Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®

  4/7/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with a large pharmaceutical company to advance its ADMET Predictor® machine learning software for use within integrated drug discovery workflows

• Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe

  4/2/2020

  Accretive acquisition adds Monolix Suite, a population PKPD modeling solution for pharmacometricians

• Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call

  4/2/2020

  Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2020 fiscal year, the period ended February 29, 2020, on Thursday, April 9, 2020.

• Simulations Plus Offers Rapid Response COVID-19 Research Initiative

  3/26/2020

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the establishment of the StrategiesPlus™ COVID-19 ACT Program to speed consulting assistance to any organization involved in coronavirus research.

• Simulations Plus to Present at the 22nd Annual Needham Growth Conference

  1/13/2020

  Simulations Plus, Inc. announced that chief executive officer Shawn O’Connor will present at the 22nd Annual Needham Growth Conference in New York City on Wednesday, January 15, 2020, at 4:50 p.m. ET.